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Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disease characterized by insidious cognitive decline
and memory dysfunction. Synapse loss is the best pathological correlate of cognitive decline in AD and mounting
evidence suggests that AD is primarily a disease of synaptic dysfunction. Soluble oligomeric forms of amyloid beta
(Ab), the peptide that aggregates to form senile plaques in the brain of AD patients, have been shown to be toxic
to neuronal synapses both in vitro and in vivo.A b oligomers inhibit long-term potentiation (LTP) and facilitate
long-term depression (LTD), electrophysiological correlates of memory formation. Furthermore, oligomeric Ab has
also been shown to induce synapse loss and cognitive impairment in animals. The molecular underpinnings of
these observations are now being elucidated, and may provide clear therapeutic targets for effectively treating the
disease. Here, we review recent findings concerning AD pathogenesis with a particular focus on how Ab impacts
synapses.
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Background
First described by the German neuropathologist Alois
Alzheimer in 1906, Alzheimer’sd i s e a s e( A D )i sap r o -
gressive neurodegenerative disease characterized by insi-
dious cognitive decline and loss of memory function
[1,2]. Over 35 million people are afflicted with AD
worldwide, 5.5 million of them in the United States
alone, and these numbers are expected to quadruple by
2050 [3]. AD is the sixth leading cause of death in the
United States, and remains one of the only causes of
death that increased by as much as 66% over the last
decade [4]. No disease-modifying drug has been devel-
oped for treating AD, making it one of the most press-
ing public health problems in the world today.
Tremendous progress has been made over the last few
decades in understanding the underlying biology of the
disease. Here we review pertinent research findings con-
cerning AD pathogenesis with a particular focus on how
neuronal synapses are impacted in disease progression.
Understanding the molecular underpinnings of AD
pathogenesis may aid in developing effective therapeutic
approaches for combating it.
Neuropathology and Pathogenesis of Alzheimer’s disease
AD is characterized pathologically by cortical atrophy,
neuronal cell death, neuroinflammation, synapse loss,
and the accumulation of two definitive pathological
lesions: neurofibrillary tangles and senile plaques [5].
Neurofibrillary tangles (NFTs) deposit within neurons
and are composed of hyperphosphoryated tau protein
whereas senile plaques occur in the extracellular space
and are made up largely of the 38-43 amino acid peptide
amyloid-beta (Ab)[ 6 ] .A b is believed to be a key trigger
of AD pathogenesis, one that is upstream of NFTs. It is
formed by the sequential cleavage of the amyloid pre-
cursor protein (APP) by b-a n dg-secretase, after which
Ab is released into the extracellular space [6]. There, Ab
can assume a variety of conformational states ranging
from monomers to soluble oligomers, protofibrils, and
fibrils, which aggregate to form plaques [7-9].
Several lines of evidence support the hypothesis that
alterations in amyloid processing can lead to AD. First,
APP is located on chromosome 21, and Down syndrome
patients who have trisomy of chromosome 21 invariably
develop AD [10]. Further, individuals with trisomy 21
with a chromosome 21q break such that APP diploidy
occurs in the setting of trisomy 21 do not develop clini-
cal or neuropathological AD [11]. Conversely, a small
cohort of patients who inherited an extra copy of APP
due to microduplication of small portions of
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AD-like dementia with plaque deposition [12].
Second, most genetic mutations associated with rare
familial early onset AD lead to increased production of
Ab or an increase in Ab42-to-Ab40 ratio, which
increases the propensity for Ab aggregation [13]. Muta-
tions leading to early onset familial AD have been found
in the APP gene on chromosome 21q [14], in the prese-
nilin 1 gene (PSEN 1) on chromosome 14q, and the pre-
senilin 2 gene (PSEN 2, a homolog of PSEN 1) located
on chromosome 1q [13]. Presinilin forms the catalytic
site of g-secretase, which is one of the enzymes involved
in the cleavage of APP to form Ab [15-17] All of these
mutations influence Ab metabolism and production
[18,19].
Third, Ab has been shown to be toxic to neurons in
vitro and in vivo [6]. Injecting synthetic or naturally
secreted Ab, at concentrations akin to those seen in the
brains of AD patients, into the brains of rodents induces
behavioral deficits and tau hyperphosphorylation [5].
Fourth, transgenic mouse models overexpressing
human APP and/or PSEN genes with known familial
early onset AD mutations develop amyloid plaque
deposition and some of the morphological changes of
AD (e.g. synapses loss) [20-22]. While most of these
transgenic mice do not develop the typical neuronal cell
loss observed in AD, they manifest age-dependent mem-
ory impairments and cognitive deficits [20-22].
Finally, immunization of AD transgenic mice with Ab
or anti-Ab antibodies reduces amyloid plaque deposi-
tion, clears existing plaques, and ameliorates cognitive
deficits in transgenic mice [23,24], indicating that
removal of Ab is beneficial to the brain.
Taken together, these findings suggest that Ab is an
essential element in the pathogenesis of AD. The
mechanistic link between Ab and neurodegeneration,
however, remains elusive. Mounting evidence suggests
that AD is primarily a disease of synaptic dysfunction
[25] and it is becoming clear that Ab, particularly in oli-
gomeric form, is toxic to synapses. There is therefore a
growing interest in understanding how oligomeric Ab
induces synaptic dysfunction in AD.
Ab-mediated synaptic dysfunction in Alzheimer’s disease
AD brains are characterized by dramatic synapses loss in
mesiotemporal regions [26-29]. Significant synapse loss
also occurs in patients with mild cognitive impairment,
a harbinger for future AD [30]. In fact, synapse loss is
the best pathological correlate of cognitive dysfunction
in AD, suggesting that synaptic changes are crucial for
AD pathogenesis [28,31,32]. Synapse loss is most promi-
nent in the immediate vicinity of senile plaques, suggest-
ing that plaques may be a reservoir of synaptotoxic
m o l e c u l e ss u c ha sA b [33-36]. Indeed, recent studies
using multiphoton in vivo imaging revealed a halo of
oligomeric Ab around plaques in the brain of AD trans-
genic mice suggesting that oligomeric Ab may exist in
equilibrium with plaques in AD [37].
Ab oligomerizes via an unknown mechanism, adopting
several higher order conformations such as soluble
dimers, trimers, dodecamers, higher order oligomers
(also named Ab-derived diffusible ligands (ADDL)), pro-
tofibrils, and fibrils [38-42]. Most of these higher order
Ab structures have been found to be toxic to neurons.
Synthetic Ab oligomers or natural soluble oligomeric
Ab purified from the media of cultured cells expressing
mutant human APP (hAPP) or extracted directly from
the brains of AD patients have potent synaptic effects.
Sodium dodecyl sulfate (SDS) stable Ab oligomers,
ADDLs and protofibrils [43-47] have all been shown to
induce synaptic dysfunction [43-48]. Specifically, oligo-
meric Ab inhibits the induction of long-term potentia-
tion (LTP), an electrophysiological correlate of memory
formation [41,44,49-53]. Biophysical methods such as
size exclusion chromatography (SEC) and mass spectro-
s c o p yh a v eb e e nu s e dt os h o wt h a tA b dimers and tri-
mers are most potent at inhibiting LTP [50,51].
Inhibitors of Ab oligomerization rescue impairment of
LTP induced by Ab containing media, suggesting that
monomeric Ab is not a potent inhibitor of LTP [54].
Complementing its effects on LTP inhibition, oligomeric
Ab has also been shown to facilitate the induction of
long-term depression (LTD) in hippocampal synapses
[52,55,56]. Impairments in LTP and facilitation of LTD
culminate in synaptic depression and impairments in
neuronal networks [57].
Molecular basis of oligomeric Ab mediated synaptic
depression
The molecular mechanisms underlying oligomeric Ab-
mediated synapse dysfunction is very complex. Oligo-
meric Ab can induce calcium dyshomeostasis, trigger
activation of caspases and calcineurin, and modulate the
activity of synaptic excitatory receptors and receptor tyr-
osine kinases, instigating a cascade of molecular events
that culminate in the inhibition of LTP, facilitation of
LTD, and synapse loss (Figure 1).
Physiologically, LTP and LTD depend on calcium
influx through N-methyl-D-aspartate (NMDA) receptors
and/or activation of metabotropic glutamate receptors
(mGluRs) [58-62]. Synapse potentiation or depression
depends on the rate of influx of calcium as well as the
level of cytosolic calcium. LTP occurs when rapid and
high levels of calcium influx occur through NMDA
receptors, whereas LTD is favored when low level cal-
cium influx through NMDA receptors occurs [63]. LTP
requires the activation of NR2A containing NMDA
receptors, whereas LTD requires activation of NR2B
containing NMDA receptors [64]. These different
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influx kinetics [65,66] and modulate distinct postsynap-
tic signaling pathways [67,68]. LTP is associated with
dendritic spine enlargement and increase in synapse
density, whereas LTD leads to dendritic spine shrinkage
and synapse collapse [69-72]. Several protein kinases
such as p38 mitogen-activated protein kinase (MAPK),
calcium calmodoulin-dependent protein kinase II (CaM-
KII), glycogen synthase kinase 3-beta (GSK3b), and
ephrin receptor B2 (EphB2) have all been shown to
modulate LTP induction in the brain [73,74]. Phospha-
tases and proteases such as calcineurin (protein phos-
phatase 2B [PP2B]) and caspases play key intracellular
roles in the induction of LTD [58,62,75]. Transcription
factors such as the cyclic AMP response element bind-
ing protein (CREB) are crucial for the induction of con-
tinuous LTP, by increasing the expression of several
genes including those encoding brain derive neuro-
trophic factor (BDNF) and nitric oxide synthase [76,77].
Oligomeric Ab has been shown to inhibit LTP and
enhance LTD by modulating the activity of all of the
above molecular pathways. Oligomeric Ab-induced loss
of excitatory synapses in the hippocampus requires
functional NMDA receptors [51]. Several studies have
shown that oligomeric Ab induces partial blockade of
NMDA receptor currents, which leads to reduction of
calcium influx into spines promoting LTD over LTP
[78,79]. Ab binds to 7a-nicotinic acetylcholine receptors
(nAchR) [80], triggering a series of events that leads to
internalization of NMDA receptors via a mechanism
requiring calcineurin activation [81]. Reduced calcium
influx through NMDA receptors induced by Ab limits
CAMKII function, LTP, and spine enlargement [82]. In
fact, oligomeric Ab-mediated LTP impairment is
believed to involve a decrease in the activation of
MAPK, CaMKII and Akt/protein kinase B, but not pro-
tein kinases A and C [53,83,84]. Ab has also been
shown to induce synaptic depression by activating
mGluRs, which triggers a series of downstream molecu-
lar events involving MAPK and calcineurin, ultimately
promoting internalization of a-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptors and
synapse collapse [73,85]. In vivo studies suggest that Ab
indirectly modulates calcineurin activation by causing
calcium dysregulation [86-88]. Calcineurin activation
promotes the induction of LTD by decreasing surface
expression of NMDA receptors and increasing internali-
zation of AMPA receptors via dynamin-mediated endo-
cytosis [79,89]. Indeed, Ab-mediated internalization of
AMPA [85] and NMDA receptors [81], loss of dendritic
spines [85], and cognitive decline [90] can all be rescued
by inhibiting calcineurin activation [91-93], indicating
that calcineurin plays a crucial role in Ab-dependent
modulation of synaptic plasticity. Further, oligomeric Ab
activation of calcineurin has been shown to induce den-
dritic simplification, spine loss, and neuritic dystrophies
at least in part by activating NFAT (nuclear factor of
activated T-cells) pathways both in vitro and in vivo
[91]. Oligomeric Ab has also been shown to activate
other synaptic phosphatases such as STEP (striatal-
enriched tyrosine phosphatase), which function to
dephosphorylate NR2B subunits of NMDA receptors
and promote their endocytosis, thereby inducing synap-
tic depression [94-96].
Figure 1 Molecular pathways of oligomeric Ab mediated
synaptic dysfunction. Oligomeric Ab (oAb) can induce calcium
dyshomeostasis, trigger activation of caspase 3, or modulate the
activity of NMDARs either directly or through intermediate
molecules (shown as X) involved in the trafficking of NMDAR (e.g.
EphB2). Activation of different subtypes of NMDA receptors may
trigger different intrasynaptic pathways. Activation of NR2A
containing NMDARs may lead to high changes in synaptic calcium
concentration ([Ca
2+]), which triggers downstream events involving
CaMKII and pCREB (not shown), facilitating the induction of LTP,
which promotes dendritic spine enlargement. Alternatively,
activation of NR2B containing NMDAR may trigger a low rise in
intrasynaptic calcium, which is favored by oAb interactions with
synapses (away from dotted line pathway), leading to calcineurin
(CaN) activation; oAb-dependent active caspase 3 can also activate
CaN. Activated CaN dephosphorylates GluR subunits of AMPARs
promoting internalization of AMPARs from the surface of synapses
leading to LTD, which leads to dendritic spine shrinkage.
Furthermore, active CaN dephosphorylates cofilin rendering it active
to depolymerize dendritic spine actin, which leads to dendritic
spine collapse and synapse loss.
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surface receptor tyrosine kinases that play key roles in
LTP and LTD modulation. For instance, it has been
shown that oligomeric Ab binds to the fibronectin
domain of EphB2, a receptor tyrosine kinase known to
modulate NMDA receptor trafficking and downstream
transcription factors such as Fos, which plays a critical
role in the induction of LTP [97-100]. Oligomeric Ab
binding to EphB2 promotes its degradation in the pro-
teasome, impairing the induction of LTP [101]. Indeed,
EphB2 is depleted in the brains of transgenic hAPP
mice and AD patients [102], and replacement of EphB2
reverses cognitive impairment in hAPP mice [101].
Other studies have shown that Ab facilitates hippo-
campal LTD via a mechanism that depends on both
NMDAR and mGluR activity. Exogenous extracellular
glutamate scavengers reverse oligomeric Ab mediated
facilitation of LTD, whereas inhibitors of glutamate
reuptake mimic oligomeric Ab-mediated LTD facilita-
tion, suggesting that the effects of oligomeric Ab-
mediated LTD facilitation may occur as a result of
impaired glutamate reuptake at the synapse, leading to
post-synaptic NMDA receptor desensitization [55].
Metabotropic glutamate receptor activity, GSK-3b sig-
naling, and protein phosphatase 2B activity are all neces-
sary for oligomeric-Ab mediated LTD enhancement
[55,73].
Caspase-3 activity has also been found to be crucial
for oligomeric Ab-mediated facilitation of LTD. Soluble
Ab induces caspase-3 activation at a low level that is
not sufficient to induce apoptosis [84]. Mitochondria-
dependent caspase-3 activation is necessary for physiolo-
gic LTD via a mechanism involving Akt proteolysis [75].
Soluble Ab activates caspase-3, which leads to LTD via
a mechanism involving activation of different protein
phosphatases that dephosphorylate AMPA receptors and
promote their endocytosis from synaptic surfaces, sug-
gesting that prevention of caspase-3 activation may be a
viable therapeutic approach for treating AD [84]. Acute
inhibition of caspase-3 activity is beneficial, but unfortu-
nately, chronic inhibition of caspase-3 activation beyond
the baseline did not reverse cognitive decline in hAPP
mice, but instead exacerbated cognitive impairment,
possibly due to a requirement for caspase-3 activity in
normal synaptic function [84]. Ab also influences CREB
activation, which is crucial for the maintenance of LTP,
insofar as CREB regulates the expression of genes neces-
sary for LTP. One study showed that Ab decreases the
activity of CREB and thus reduces expression of genes
encoding proteins that aree s s e n t i a lf o rL T P[ 1 0 3 ] .
Another study found that excessive activation of extrasy-
naptic NR2B-containing NMDA receptors, which leads
to downregulation of CREB underlies oligomeric Ab-
mediated LTP inhibition [104].
Oligomeric Ab causes synapse shrinkage in Alzheimer’s
disease
The acute effects of Ab on synaptic physiology appear
to translate into structural changes in synaptic mor-
phology because enhanced LTD leads to dendritic
spine shrinkage whereas inhibition of LTP limits spine
enlargement [69-72]. Exposure of cultured neurons or
rat hippocampal slices to oligomeric Ab induces den-
dritic spine shrinkage and collapse, a phenomenon that
can be reversed by treatment with Ab antibodies
[51,105]. APP transgenic mice have significant synapse
loss and neutralization of oligomeric Ab with anti-Ab
antibodies leads to reversal of synapse collapse
[106-108]. Furthermore, increased concentration of Ab
may reduce glutamatergic transmission and leads to
synapse loss in hAPP transgenic mice even before pla-
que formation [21,109,110]. Oligomeric Ab-mediated
inhibition of LTP and enhancement of LTD lead to
dendritic spine loss as a result of F-actin remodeling
[105]. LTD accompanied by shrinkage of dendritic
spines occurs via a mechanism involving cofilin-
mediated depolymerization of actin [71]. Specifically,
Ab indirectly stimulates cof i l i nb i n d i n gt oa c t i na n d
induction of actin depolymerization in neuronal cytos-
keleton. Binding of cofilin to actin is promoted by
dephosphorylation at Ser3 by phosphatase Slingshot,
and inhibited by phosphorylation by LIM kinase 1, a
process that is modulated by oligomeric Ab [105].
Indeed, in addition to dendritic spine protein loss,
increased amounts of dephosphorylated cofilin have
been found in the brain of AD patients [111,112].
Oligomeric Ab induces cognitive impairments
The electrochemical and structural effects of oligomeric
Ab on synapses described above may lead to potent
behavioral and cognitive deficits in animals. Intra-cere-
bral injection of synthetic or naturally secreted oligo-
meric Ab impairs complex behavior including memory
and cognitive function in animals [113-115]. APP trans-
genic mice with increased soluble Ab in the brain dis-
play dramatic cognitive impairments even before the
onset of plaque deposition [21]. Neutralization of solu-
ble oligomeric Ab with anti-Ab antibodies reverses
behavioral deficits seen in different AD transgenic mice
[116-118], suggesting that behavioral deficits in AD
transgenic mice are caused by soluble Ab. Inhibition of
oligomeric Ab formation decreases both histopathologi-
cal and behavioral AD phenotypes in APP transgenic
mice [119], implicating higher order Ab structures such
as soluble oligomeric Ab, but not Ab monomers, in AD
pathogenesis. Levels of soluble oligomeric Ab,b u tn o t
senile plaques, in the brain correlates with severity of
memory loss in human AD patients, however, the pre-
cise contribution of different Ab species to cognitive
decline is not clear [120].
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meric Ab levels in the brain leads to synaptic dysfunc-
tion, it should be noted that at physiologic levels, Ab
might play a normal role in modulating synaptic activity,
which likely becomes deranged in the setting of excess
Ab production or accumulation, leading ultimately to
the clinical manifestation of cognitive impairment.
Indeed, there is a small but growing body of evidence
suggesting that Ab at low concentrations actually pro-
motes LTP and normal synaptic function [121-124].
Thus, therapeutic approaches aimed at improving cogni-
tion by counteracting the toxic effects of Ab will have to
be tailored to target only the toxic function of oligo-
meric Ab. Nonspecific total inhibition of Ab may lead
to negative effects on synaptic function and cognition.
Seeing Ab in action at synapses
Collectively, all of the above evidence suggests that solu-
b l eo l i g o m e r i cA b is a potent mediator of cognitive
impairment in AD. Oligomeric Ab inhibits the induction
of LTP, lowers the threshold for inducing LTD, and
causes synapse collapse, which may ultimately lead to
cognitive decline resulting from disrupted neuronal net-
work connectivity [57]. For several years, limitations in
the resolution of conventional microscopy techniques
made it difficult to ascertain whether oligomeric Ab
directly associates with neuronal synapses and plays a
role in their shrinkage and collapse in vivo. Recent
advances in high-resolution microscopy techniques have
made it possible to address these questions. For example
development of array tomography [125,126], an ultra-
high resolution fluorescence imaging technique that
allow direct simultaneous visualization of several thou-
sand small structures such as synapses and peptides in
tissue has allowed determination of whether oligomeric
Ab plays a direct role in synapse loss in AD. Using
array tomography and a conformation specific antibody
(NAB61) [127], we demonstrated that oligomeric Ab in
the brain of APP/PS1 transgenic mice directly coloca-
lizes with a subset of synapses and is associated with
their shrinkage and collapse [37] (Figure 2), suggesting
that the in vitro effects of Ab oligomers observed using
cell based assays likely also occur in vivo, supporting the
notion that oligomeric Ab adversely impacts synapses.
High-resolution techniques such as array tomography
could be extended to study the effects of oligomeric Ab
on synapses in the brain of AD patients. Furthermore, it
will be important to determine whether Ab oligomers
are targeted to synapses by specific carrier proteins or
whether they are produced locally at synapses. A num-
ber of studies have suggested that production of Ab (at
least in monomeric form) is regulated by activity
[110,128-130] and Ab appears to play a negative feed-
back function on synaptic activity [110,131,132].
Mechanistically, synaptic activity-dependent production
of Ab requires clathrin-mediated endocytosis of APP,
which is then cleaved by b- and g-secretase in late endo-
somes at synapses to form Ab [129]. Nonetheless, it is
also possible that Ab binding proteins like apolipopro-
tein E, which also play a role at the synapse, may stabi-
lize Ab oligomers [133] in the extracellular space and
deliver them to synaptic sites.
It is presently unclear whether Ab oligomers interact
directly with specific high affinity receptors at the
synapse to induce synapse dysfunction. A number of
recent studies have reported high affinity binding of oli-
gomeric Ab to cellular prion protein (PrP
C), which was
necessary for Ab to mediate acute synaptic depression,
synapse loss, and cognitive impairment in vivo
[134,135]. Subsequent studies, however, could not repro-
duce these findings [136-138]. This is likely because of
differences in experimental paradigms used in the subse-
quent studies. Single particle tracking of Ab oligomers
labeled with quantum dots exposed to hippocampal
Figure 2 Oligomeric Ab associates with a subset of synapses in the brain of Alzheimer’s disease transgenic mice. A) Array tomograms
showing oligomeric Ab (oAb) localized to synaptic sites near senile plaques in APP/PS1 mice. B) A higher magnification view of the outlined
square in panel A showing multiple pre- and post-synaptic elements colocalized with oAb (arrows) stained with an oAb specific antibody
(NAB61). Scale bar is 10 μmi nA and 2 μmi nB.
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the diffusion of Ab oligomers is dramatically limited
upon binding to synaptic sites, suggesting that high affi-
nity oligomeric Ab receptors may be present at synapses
[139]. Identifying these high affinity receptors could aid
in designing drugs capable of blocking the deleterious
effects of oligomeric Ab on neuronal synapses.
Concluding remarks
Based on the evidence discussed here, we postulate that
AD begins as a disease of synaptic dysfunction and
synapse loss then progresses to include widespread neu-
ronal loss and neuronal network failure. Findings from
recent experiments continue to provide insight into the
complicated molecular underpinnings of synapse dys-
function in AD with mounting evidence pointing to
soluble oligomeric Ab as a key player in the induction
of synaptic failure. Oligomeric Ab activates a variety of
molecular cascades that culminate in synapse dysfunc-
tion, shrinkage, collapse and loss (Figure 1). These
pathological Ab-triggered molecular events, however,
may become independent of Ab as the disease pro-
gresses, with downstream tau effects causing overt neu-
ronal loss, exacerbating the loss of connectivity between
neurons [140]. If this is correct, at least two main thera-
peutic approaches could be taken to combat the disease
effectively: 1) early interventions that prevent the initia-
tion of Ab-triggered pathological events; or 2) inhibition
of specific downstream pathways activated by Ab.T h e
failure of previous therapeutic approaches aimed at
removing toxic Ab species from the brain (e.g. active
immunization with Ab peptide) in clinical trials may be
because they were given to the wrong cohort of patients
(i.e. patients with advanced AD, whose Ab-triggered
neuronal events may have become independent of Ab)
[140]. Perhaps, a more effective approach will be to
initiate such anti-Ab therapeutic regimens at very early
stages of the disease. For this approach to be successful,
highly sensitive and specific biomarkers for diagnosing
AD need to be developed to identify AD patients at the
very early stages of the disease. For patients who have
progressed into symptomatic AD, it will likely be neces-
sary to target pathways downstream of Ab,i n c l u d i n g
tau hyperphosphorylation and accumulation in the
soma, which are linked to neuronal death [141,142]. In
conclusion, Ab-mediated synaptic dysfunction appears
to be an important driving factor in AD pathogenesis
and understanding the molecular underpinnings may
provide effective therapeutic targets for combating the
disease.
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